Bristol-Myers (BMS) Collaborates with Vedanta Biosciences to Develop Combination Therapy for Advanced or Metastatic Cancers


  • BMS to make equity investment in Vedanta and Vedanta will evaluate Opdivo + VE800, for advanced or metastatic cancers
  • The focus of the collaboration is to develop combination therapy and to research aspect of microbes in advanced or metastatic cancers
  • Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor, approved to treat multiple cancer. VE800 is a bacterial consortium used for activating cytotoxic CD8+ T cells

Click here to read full press release/ article | Ref: BMS | Image: Barrons

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at

Related post